Neoadjuvant Trastuzumab Deruxtecan Plus Paclitaxel, Trastuzumab, and Pertuzumab Improves Pathological Complete Response and Safety in High-Risk HER2-Positive Early Breast Cancer: DESTINY-Breast11 Phase 3 Trial - Vera Health News